- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 56211-40-6] Torsemide
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B0247 |
| Brand: | MCE |
| CAS: | 56211-40-6 |
Overview
| MDL | MFCD00866166 |
|---|---|
| Molecular Weight | 348.42 |
| Molecular Formula | C16H20N4O3S |
| SMILES | O=S(C1=C(NC2=CC=CC(C)=C2)C=CN=C1)(NC(NC(C)C)=O)=O |
Summary
In Vitro
Torsemide binds reversibly to Na
+
/2Cl
-
/K
+
cotransporter carrier protein, thus reducing or abolishing NaCl reabsorption
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00602303 | Roxane Laboratories|West-Ward Pharmaceutical |
Edema
|
September 2003 | Not Applicable |
| NCT05093621 | Yale University |
Heart Failure
|
February 8, 2021 | Phase 3 |
| NCT02813551 | The University of Texas Health Science Center, Houston |
Preeclampsia
|
August 2016 | Phase 2 |
| NCT01558674 | Merck Sharp & Dohme LLC |
Renal Impairment|Heart Failure
|
May 23, 2014 | Phase 1 |
| NCT00602615 | Roxane Laboratories|West-Ward Pharmaceutical |
Edema
|
September 2003 | Not Applicable |
| NCT01788254 | Matthias Schwab|University Hospital Tuebingen |
Genotype-related Drug Metabolism
|
January 2012 | Phase 1 |
| NCT00409942 | Ferrer Internacional S.A. |
Congestive Heart Failure
|
March 2007 | Phase 4 |
| NCT01942109 | Medical University of Warsaw |
Heart Failure
|
September 2013 | Phase 4 |
| NCT03509545 | Sarfez Pharmaceuticals, Inc. |
Body Weight Changes
|
June 30, 2021 | Phase 1 |
| NCT03354897 | NHS Greater Glasgow and Clyde|University of Glasgow|British Heart Foundation |
Cardiovascular Diseases|Hypertension
|
April 5, 2017 | Phase 4 |
| NCT02087332 | Society of Specialists in Heart Failure |
Arterial Hypertension|Chronic Heart Failure
|
April 2014 | Phase 4 |
| NCT01276288 | Boehringer Ingelheim |
Diabetes Mellitus, Type 2
|
January 2011 | Phase 1 |
| NCT04921566 | Pharmtechnology LLC|ClinPharmInvest, LLC |
Bioequivalence
|
June 5, 2021 | Phase 1 |
| NCT03215875 | Sarfez Pharmaceuticals, Inc. |
Food-drug Interaction
|
October 17, 2017 | Phase 1 |
| NCT01845194 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH |
Drug Biotransformation|Membrane Transport
|
December 2009 | Phase 1 |
| NCT03214874 | Sarfez Pharmaceuticals, Inc. |
Congestive Heart Failure|Chronic Kidney Diseases
|
June 19, 2017 | Phase 1 |
| NCT03187509 | New York City Health and Hospitals Corporation |
Heart Failure
|
April 17, 2018 | Phase 4 |
| NCT00654043 | Par Pharmaceutical, Inc.|Anapharm |
Healthy
|
April 2001 | Phase 1 |
| NCT00653549 | Par Pharmaceutical, Inc.|Anapharm |
To Determine Bioequivalence Under Fasting Conditions
|
April 2001 | Phase 1 |
| NCT00334386 | Ferrer Internacional S.A. |
Hypertension
|
April 2005 | Phase 4 |
| NCT03296813 | Duke University|National Heart, Lung, and Blood Institute (NHLBI)|Yale University |
Heart Failure
|
July 11, 2018 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 71.75 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8701 mL | 14.3505 mL | 28.7010 mL |
| 5 mM | 0.5740 mL | 2.8701 mL | 5.7402 mL |
| 10 mM | 0.2870 mL | 1.4350 mL | 2.8701 mL |
References
- [1] Ishido, H., et al. Torasemide for the Treatment of Heart Failure. Cardiovascular & Hematological Disorders-Drug Targets. 2008. 8(2), 127–132.
- [2] Goodfriend, T. L., et al. Torsemide inhibits aldosterone secretion in vitro. Life Sciences. 1998. 63(3), PL45–PL50.
- [3] H A Friedel, et al. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs. 1991 Jan;41(1):81-103.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.